13F Holdings
中文EN

IMTX Immatics N.V. IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1809196 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-1,390.9%
TTM EPS YoY-1,250.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-37.1%
ROA-31.2%
ROIC (approx.)-60.4%
Asset turnover—

Leverage & solvency

Liabilities / assets13.9%
Debt / equity0.00x
Current ratio11.72x
Interest coverage-192.41x

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-3.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR FY2025*2025-12-31FY2024*2024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense183.83M148.08M118.66M106.78M87.57M
SG&A expense51.18M46.45M38.20M36.12M33.81M
Operating income-182.02M-38.62M-101.72M29.95M-86.29M
Interest expense946,000886,000831,0001.04M566,000
Pretax income-198.44M21.35M-96.99M42.04M-93.33M
Income tax-1.99M6.13M-2.35M14.33M0
Net income-196.45M15.22M-94.65M27.70M-93.33M
EBITDA-169.62M-26.39M-94.49M36.92M-81.03M
EPS (basic)-1.610.14-1.180.41-1.48
EPS (diluted)-1.610.14-1.180.40-1.48
Weighted avg. shares (diluted)122.35M106.80M80.55M68.82M62.91M
Balance sheet
Cash & equivalents345.92M236.75M218.47M148.52M132.99M
Receivables6.10M5.86M4.09M1.11M682,000
Current assets504.01M629.55M449.37M377.15M152.21M
PP&E, netmay include right-of-use assets (IFRS)42.11M50.38M43.75M13.46M10.51M
Intangibles1.58M1.63M1.52M1.63M1.31M
Total assets562.34M696.15M509.96M407.82M174.65M
Current liabilities43.01M67.99M156.55M106.45M95.15M
Total liabilities78.24M121.30M292.35M204.47M150.58M
Shareholders' equity484.10M574.84M217.62M203.35M24.06M
Shares outstanding————62.93M
Cash flow statement
Operating cash flow-176.63M-158.03M18.23M100.13M-84.75M
Capital expenditure6.56M16.27M30.80M5.74M5.11M
Free cash flow-183.18M-174.30M-12.57M94.39M-89.85M
Investing cash flow204.79M-152.39M-31.39M-209.79M7.49M
Financing cash flow97.35M319.68M84.52M123.71M-2.61M
Depreciation & amortization12.40M12.22M7.23M6.97M5.26M
Stock-based compensation15.02M17.64M20.70M22.57M26.40M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.